Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Edema | 5 | 2022 | 7 | 2.490 |
Why?
|
| Uveitis | 8 | 2021 | 9 | 2.130 |
Why?
|
| Uveitis, Posterior | 3 | 2020 | 3 | 0.990 |
Why?
|
| Adalimumab | 3 | 2020 | 15 | 0.970 |
Why?
|
| Sirolimus | 3 | 2020 | 14 | 0.940 |
Why?
|
| Posterior Eye Segment | 2 | 2020 | 2 | 0.800 |
Why?
|
| Diabetic Retinopathy | 1 | 2022 | 5 | 0.790 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 113 | 0.730 |
Why?
|
| Intravitreal Injections | 6 | 2022 | 10 | 0.650 |
Why?
|
| Rituximab | 2 | 2019 | 36 | 0.640 |
Why?
|
| Immunologic Factors | 1 | 2019 | 26 | 0.610 |
Why?
|
| Rickettsia Infections | 1 | 2016 | 1 | 0.500 |
Why?
|
| Retinitis | 1 | 2016 | 2 | 0.500 |
Why?
|
| Eye Infections, Bacterial | 1 | 2016 | 9 | 0.500 |
Why?
|
| Tomography, Optical Coherence | 5 | 2021 | 12 | 0.470 |
Why?
|
| Glucocorticoids | 4 | 2022 | 59 | 0.450 |
Why?
|
| Visual Acuity | 6 | 2021 | 40 | 0.450 |
Why?
|
| Triamcinolone Acetonide | 3 | 2021 | 7 | 0.410 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 91 | 0.380 |
Why?
|
| Double-Blind Method | 4 | 2020 | 367 | 0.370 |
Why?
|
| Humans | 21 | 2022 | 24703 | 0.360 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 104 | 0.320 |
Why?
|
| Panuveitis | 2 | 2020 | 2 | 0.320 |
Why?
|
| Uveitis, Intermediate | 2 | 2020 | 2 | 0.320 |
Why?
|
| Treatment Outcome | 8 | 2021 | 3208 | 0.320 |
Why?
|
| Female | 11 | 2020 | 14048 | 0.280 |
Why?
|
| Middle Aged | 11 | 2020 | 8294 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 314 | 0.230 |
Why?
|
| Time Factors | 4 | 2020 | 1327 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2022 | 3156 | 0.210 |
Why?
|
| Vision Disorders | 2 | 2019 | 18 | 0.200 |
Why?
|
| Aged | 8 | 2020 | 8382 | 0.200 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 1 | 0.200 |
Why?
|
| Drug Implants | 1 | 2022 | 8 | 0.200 |
Why?
|
| Male | 10 | 2021 | 13669 | 0.190 |
Why?
|
| Treatment Failure | 2 | 2020 | 145 | 0.190 |
Why?
|
| Choroid Diseases | 1 | 2002 | 2 | 0.190 |
Why?
|
| Retinal Diseases | 1 | 2002 | 4 | 0.190 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2021 | 1 | 0.190 |
Why?
|
| Strongylida Infections | 1 | 2021 | 1 | 0.190 |
Why?
|
| Retinal Detachment | 1 | 2021 | 7 | 0.190 |
Why?
|
| Adult | 8 | 2020 | 7255 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2019 | 65 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1671 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2019 | 315 | 0.170 |
Why?
|
| Intraocular Pressure | 1 | 2020 | 7 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 75 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 138 | 0.160 |
Why?
|
| Uveitis, Anterior | 1 | 2019 | 2 | 0.160 |
Why?
|
| Spondylarthropathies | 1 | 2019 | 3 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 303 | 0.160 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 13 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 117 | 0.150 |
Why?
|
| Prospective Studies | 1 | 2022 | 1612 | 0.140 |
Why?
|
| Retina | 1 | 2016 | 7 | 0.130 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 2 | 2008 | 3 | 0.130 |
Why?
|
| Chorioretinitis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Rickettsia | 1 | 2016 | 1 | 0.120 |
Why?
|
| Africa | 1 | 2016 | 9 | 0.120 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 14 | 0.120 |
Why?
|
| Travel | 1 | 2016 | 13 | 0.120 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 1 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 25 | 0.110 |
Why?
|
| Lymphoma | 1 | 2013 | 34 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 157 | 0.100 |
Why?
|
| Ocular Hypotension | 1 | 2012 | 1 | 0.100 |
Why?
|
| Eye Infections, Viral | 1 | 2008 | 3 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2008 | 13 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 39 | 0.070 |
Why?
|
| Young Adult | 3 | 2020 | 1847 | 0.070 |
Why?
|
| Animals | 3 | 2021 | 3330 | 0.060 |
Why?
|
| Risk Factors | 2 | 2019 | 2099 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 25 | 0.060 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2004 | 4 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 411 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4509 | 0.050 |
Why?
|
| Exudates and Transudates | 1 | 2002 | 1 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2002 | 7 | 0.050 |
Why?
|
| Hawaii | 1 | 2021 | 2 | 0.050 |
Why?
|
| Magnolia | 1 | 2021 | 1 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 21 | 0.040 |
Why?
|
| Women's Health | 1 | 2002 | 135 | 0.040 |
Why?
|
| Rats | 1 | 2021 | 609 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 1992 | 0.040 |
Why?
|
| Computer Systems | 1 | 2018 | 6 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 26 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 412 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 193 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 437 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 674 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 598 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 858 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 145 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 160 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 158 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 384 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 315 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 814 | 0.020 |
Why?
|
| Acyclovir | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2008 | 8 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 39 | 0.020 |
Why?
|
| Prednisone | 1 | 2008 | 61 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 155 | 0.020 |
Why?
|